Drug Trial Radar · NCT04225208
Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jan 6, 2020
Primary completion
Mar 2, 2020
Study completion Mar 2, 2020
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I, open label, healthy volunteers, ADME study with single oral administration of \[14C\]-AZD4205.
Conditions
- Healthy Volunteers
Interventions
[14C]-AZD4205, single 50 mg oral dose administrated on day 1Drug
Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of radioactive dose recovered in urine and faeces and total percentageTime frame: Up to 57 days
- Provide samples for subsequent studiesTime frame: Up to 57 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron CPC
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.